The Cooper Companies income statement
In fiscal 2025, The Cooper Companies reported revenue of $4.09bn, up 5.1% on the year before, operating income of $683m (a 16.7% margin) and net income of $375m, or $1.87 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2009Oct 2009 | 2010Oct 2010 | 2011Oct 2011 | 2012Oct 2012 | 2013Oct 2013 | 2014Oct 2014 | 2015Oct 2015 | 2016Oct 2016 | 2017Oct 2017 | 2018Oct 2018 | 2019Oct 2019 | 2020Oct 2020 | 2021Oct 2021 | 2022Oct 2022 | 2023Oct 2023 | 2024Oct 2024 | 2025Oct 2025 | LTMJul 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,080 | 1,159 | 1,331 | 1,445 | 1,588 | 1,718 | 1,797 | 1,967 | 2,139 | 2,533 | 2,653 | 2,431 | 2,923 | 3,308 | 3,593 | 3,895 | 4,092 | 4,237 |
| Cost of revenue | 484 | 482 | 526 | 521 | 561 | 626 | 727 | 794 | 773 | 901 | 897 | 896 | 967 | 1,169 | 1,235 | 1,300 | 1,410 | 1,444 |
| Gross profit | 596 | 677 | 805 | 924 | 1,027 | 1,092 | 1,070 | 1,173 | 1,366 | 1,632 | 1,757 | 1,535 | 1,956 | 2,140 | 2,358 | 2,596 | 2,682 | 2,793 |
| Research and development | 33 | 35 | 44 | 52 | 59 | 66 | 70 | 65 | 69 | 85 | 87 | 93 | 93 | 110 | 137 | 155 | 172 | 170 |
| Selling, general and administrative | 392 | 433 | 513 | 565 | 611 | 683 | 713 | 723 | 799 | 973 | 996 | 993 | 1,211 | 1,342 | 1,501 | 1,534 | 1,628 | 1,887 |
| Operating income | 150 | 190 | 228 | 283 | 306 | 306 | 237 | 324 | 429 | 403 | 547 | 312 | 506 | 508 | 533 | 706 | 683 | 544 |
| Interest expense | 44 | 37 | 17 | 12 | 9 | 8 | 18 | 26 | 33 | 83 | 68 | 37 | 23 | 57 | 105 | 114 | 100 | 89 |
| Income before tax | 115 | 124 | 193 | 275 | 312 | 297 | 216 | 296 | 394 | 332 | 477 | 267 | 492 | 475 | 413 | 582 | 567 | 462 |
| Income tax | 14 | 12 | 17 | 27 | 15 | 25 | 10 | 21 | 21 | 192 | 11 | 28 | −2,453 | 90 | 119 | 190 | 192 | −108 |
| Net income | 101 | 113 | 175 | 248 | 296 | 270 | 204 | 274 | 373 | 140 | 467 | 238 | 2,945 | 386 | 294 | 392 | 375 | 570 |
| Diluted EPS | $0.55 | $0.61 | $0.91 | $1.26 | $1.49 | $1.38 | $1.03 | $1.40 | $1.88 | $0.70 | $2.33 | $1.20 | $14.79 | $1.94 | $1.48 | $1.96 | $1.87 | $2.91 |
| Diluted shares (average) | 182m | 186m | 193m | 197m | 199m | 196m | 197m | 196m | 198m | 199m | 200m | 198m | 199m | 199m | 199m | 200m | 200m | 196m |
| EBITDA | 242 | 284 | 326 | 395 | 431 | 445 | 428 | 522 | 618 | 678 | 828 | 462 | 815 | 854 | 901 | 1,081 | 1,060 | 834 |
| Quarter | 2024 Q4Oct 2024 | 2025 Q1Jan 2025 | 2025 Q2Apr 2025 | 2025 Q3Jul 2025 | 2025 Q4Oct 2025 | 2026 Q1Jan 2026 | 2026 Q2Apr 2026 | 2026 Q3Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,018 | 965 | 1,002 | 1,060 | 1,065 | 1,024 | 1,082 | 1,066 |
| Cost of revenue | 341 | 305 | 323 | 368 | 414 | 329 | 346 | 354 |
| Gross profit | 678 | 660 | 679 | 692 | 651 | 695 | 735 | 712 |
| Research and development | 38 | 41 | 46 | 45 | 41 | 44 | 43 | 42 |
| Selling, general and administrative | 391 | 388 | 399 | 422 | 419 | 390 | 676 | 401 |
| Operating income | 198 | 182 | 185 | 176 | 140 | 213 | −31 | 222 |
| Interest expense | 27 | 26 | 24 | 25 | 24 | 22 | 21 | 22 |
| Income before tax | 169 | 153 | 145 | 152 | 117 | 192 | −48 | 202 |
| Income tax | 51 | 49 | 57 | 54 | 32 | 61 | 30 | −231 |
| Net income | 118 | 104 | 88 | 98 | 85 | 131 | −78 | 433 |
| Diluted EPS | $0.59 | $0.52 | $0.44 | $0.49 | $0.42 | $0.66 | −$0.40 | $2.24 |
| EBITDA | 289 | 273 | 228 | 221 | 239 | 308 | 17 | 270 |
Compare with peers
- Align Technology income statement
- Dentsply Sirona Inc. income statement
- West Pharmaceutical Services income statement
- Envista Holdings Corp income statement
- ICU Medical Inc income statement
Head to head: ALGN vs COOCOO vs XRAYCOO vs WST
More: Health Care Supplies stocks compared, Health Care sector, rankings of US companies